Insys Therapeutics,'s Revenue in the fiscal year 2018 $ 82.08 millions
Insys Therapeutics,'s Revenue in the fiscal year 2017 $ 140.69 millions
Insys Therapeutics,'s Revenue in the fiscal year 2016 $ 242.28 millions
Insys Therapeutics,'s Revenue in the fiscal year 2015 $ 330.80 millions
Insys Therapeutics,'s Revenue in the fiscal year 2014 $ 222.13 millions
INSY Revenue first quarter 2019 Y/Y Growth Comment
Insys Therapeutics, Inc. reported drop in Revenue in the first quarter 2019 by -68.09% to $ 7.63 millions, from the same quarter in 2018. This represents worst decline in recent Company history.
Looking into first quarter 2019 results within Major Pharmaceutical Preparations industry 249 other companies have achieved higher Revenue growth. While Insys Therapeutics, Inc.' s Revenue meltdown of -68.09% ranks overall at the positon no. 4361 in the first quarter 2019.
Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019
Insys Therapeutics,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
98.71 %
5.02 %
-53.35 %
(Dec 31 2014)
INSY's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2019 Insys Therapeutics, Inc. disclosed fall in Revenue from the fourth quarter by -53.36% to $ 7.63 millions, from $ 16.36 millions achived in the previous reporting period.
But that's not important problem, as Insys Therapeutics,'s Revenue generally seem to plunge in this quarter.
Within Major Pharmaceutical Preparations industry 198 other companies have achieved higher Revenue quarter on quarter growth. While Insys Therapeutics,'s Revenue growth quarter on quarter, overall rank is 3676.
In the I. Quarter 2019 Insys Therapeutics, Inc. disclosed fall in Revenue from the fourth quarter by -53.36% to $ 7.63 millions, from $ 16.36 millions achived in the previous reporting period.
But that's not important problem, as Insys Therapeutics,'s Revenue generally seem to plunge in this quarter.
Within Major Pharmaceutical Preparations industry 198 other companies have achieved higher Revenue quarter on quarter growth. While Insys Therapeutics,'s Revenue growth quarter on quarter, overall rank is 3676.
Insys Therapeutics,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2019)
12 Months Ending (Dec 31 2018)
12 Months Ending (Sep 30 2018)
12 Months Ending (Jun 30 2018)
12 Months Ending (Mar 31 2018)
Cumulative Revenue 12 Months Ending
$ 65.80
$ 82.08
$ 97.21
$ 109.53
$ 128.64
Y / Y Revenue Growth (TTM)
-48.85 %
-41.66 %
-40.75 %
-42.7 %
-40.94 %
Year on Year Revenue Growth Overall
Ranking
# 3616
# 3132
# 3354
# 3287
# 3138
Seqeuential Revenue Change (TTM)
-19.84 %
-15.56 %
-11.25 %
-14.86 %
-8.57 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 3208
# 3455
# 3565
# 3548
# 3452
Cumulative Revenue growth Comment
Insys Therapeutics,'s cumulative 12 months Revenue continue to drop, but on the faster rate at -48.85% year on year, at Mar 31 2019 compare to the -41.66% decrease at Dec 31 2018. If the Insys Therapeutics,'s fiscal year would end at Mar 31 2019, annual Revenue would be $66 millions.
In the Healthcare sector 457 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3132 to 3616.
Insys Therapeutics,'s cumulative 12 months Revenue continue to drop, but on the faster rate at -48.85% year on year, at Mar 31 2019 compare to the -41.66% decrease at Dec 31 2018. If the Insys Therapeutics,'s fiscal year would end at Mar 31 2019, annual Revenue would be $66 millions.
In the Healthcare sector 457 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3132 to 3616.
About Insys Therapeutics, Revenue Growth Rates (INSY), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
